此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pembrolizumab 每 12 周一次对比每 3 周一次治疗非小细胞肺癌患者

2026年10月1日 更新者:Roswell Park Cancer Institute

Pembrolizumab 200mg 每 12 周与每 3 周一次的随机 II 期研究在 NSCLC 中对 Pembrolizumab 单药治疗具有临床益处:多中心国际研究

This phase II trial studies how well pembrolizumab given every 12 weeks works compared to every 3 weeks in treating patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab every 12 weeks may provide similar disease control with fewer treatments for patients with non-small cell lung cancer when compared to every 3 weeks. Demonstrating that 12 week dosing is as effective as 3 week dosing may also have a significant impact when considering the cost required for these medications.

研究概览

地位

主动,不招人

详细说明

PRIMARY OBJECTIVES:

I. To evaluate the 1-year progression-free survival rate with 200mg pembrolizumab administered every 3 weeks compared to 200mg pembrolizumab administered every 12 weeks.

SECONDARY OBJECTIVES:

I. To assess overall survival between the two treatment groups. II. To assess the serious adverse event profiles between the two treatment groups.

EXPLORATORY OBJECTIVES:

I. To evaluate circulating biomarkers of treatment response and resistance. II. To characterize fecal microbiotic profile and to correlate those results with tumor characteristics and antitumor immune responses.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive pembrolizumab intravenously (IV) over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, and then every 12 weeks for at least 12 months.

研究类型

介入性

注册 (实际的)

9

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • Buffalo、New York、美国、14263
        • Roswell Park Cancer Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 at the time of study treatment initiation.
  • Have pathologically confirmed diagnosis of non-small cell lung cancer (NSCLC). Mixed small cell lung cancer (SCLC) histology is not allowed.
  • Must be eligible for treatment with pembrolizumab as standard of care (up to third line).
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L.
  • Platelets >= 100 x 10^9/L.
  • Hemoglobin >= 9 g/dL.
  • Plasma creatinine =< 1.5 x institution upper limit of normal (ULN) or estimated glomerular filtration rate (GFR) (measured or calculated with Cockcroft and Gault formula) > 45 ml/min.
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (ALT and AST =< 5 x ULN is acceptable if liver metastases are present).
  • Total plasma bilirubin =< 1.5 x ULN. For patients with well documented Gilbert?s syndrome, total bilirubin =< 3 x ULN with direct bilirubin within normal range.
  • Must have demonstrated complete response, partial response by Response Evaluation Criteria in Solid Tumors (RECIST) or stable disease if > 5% but less than 30% decrease from baseline total tumor burden (target lesions) to pembrolizumab at the time of randomization for study treatment.Patients with new brain metastasis isolated in the brain while on pembrolizumab monotherapy will be eligible as long as extracranial disease control fulfills the criteria otherwise (i.e. this will not be considered as disease progression for the purpose of this study).
  • Must have received at least 6 months of pembrolizumab monotherapy treatment (but no more than 15 months total duration, including treatment in combination with chemotherapy prior to maintenance phase) prior to start of protocol-assigned treatment.
  • Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

  • Receipt of anticancer chemotherapy, other than pembrolizumab, within 6 months prior to randomization.
  • Disease progression to pembrolizumab as assessed by immune related (ir)RECIST.
  • Prior radiotherapy or gamma knife within 2 weeks of study treatment for non-brain metastasis. Subjects must have recovered from all radiation related toxicities.
  • Active/untreated brain metastasis. Whole brain radiation or gamma knife radiosurgery performed less than 4 weeks prior to first administration of study drug. Previously treated brain metastasis allowed as long as not requiring steroids and stable on imaging at least 4 weeks after completing radiation therapy.
  • Leptomeningeal involvement regardless of tumor response status.
  • Tumor with mutation that is known to be sensitive to Food and Drug Administration (FDA)- approved targeted therapy.
  • Patients who had pembrolizumab interrupted for more than 4 weeks for management of treatment-related adverse event.
  • Currently receiving or has received high-dose systemic corticosteroids within 4 weeks prior to starting study drug for management of brain metastases, or who have not fully recovered from side effects of such treatment. Patients who are on low-dose prednisone (10 mg once daily or less) for at least 6 months for the management of other chronic disorders (e.g. chronic obstructive pulmonary disease [COPD]) is allowed. Steroids for endocrine replacement or receipt of short-course of steroids during the preceding 4 week period as supportive medication such as for drug allergy, anti-emetic, etc. is allowed.
  • Had major surgery within 14 days prior to starting protocol treatment.
  • Active, clinically serious infections or other serious uncontrolled medical conditions.
  • Pregnant or nursing female participants.
  • Any condition which in the investigator?s opinion deems the participant an unsuitable candidate to receive study drug.
  • Unwilling or unable to follow protocol requirements.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Arm I (200mg pembrolizumab 3 weeks)

Patients receive 200mg pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.

Given IV

其他名称:
  • 可瑞达
  • MK-3475
  • 兰博利珠单抗
  • SCH 900475
实验性的:Arm II (200mg pembrolizumab 12 weeks)

Patients receive 200mg pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.

Given IV

其他名称:
  • 可瑞达
  • MK-3475
  • 兰博利珠单抗
  • SCH 900475

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
1-year Progression-free Survival (PFS)
大体时间:12 months from the start of first cycle of standard dose-schedule of pembrolizumab treatment

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

12 months from the start of first cycle of standard dose-schedule of pembrolizumab treatment

次要结果测量

结果测量
措施说明
大体时间
Overall Survival
大体时间:12 months after treatment completion to up to 62 months.

Defined as the number of months between Loading Phase enrollment and death from any cause. Analysis of overall survival between the two treatment groups will be carried forth using a log-rank test accounting for the stratification factors, including other known variables such as PD-L1 tumor proportion score, line of therapy, histology, mutation profile.

12 months after treatment completion to up to 62 months.
Incidence of Adverse Events
大体时间:Up to 12 months

Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Will be assessed through the evaluation of grade 3 or higher toxicities deemed possibly related to treatment. Both efficacy and toxicity rates will be estimated using simple relative frequencies. The corresponding 95% confidence intervals for the estimated probabilities will be computed.

Up to 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Grace K Dy、Roswell Park Cancer Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年8月13日

初级完成 (实际的)

2025年3月14日

研究完成 (估计的)

2026年12月14日

研究注册日期

首次提交

2019年7月18日

首先提交符合 QC 标准的

2019年7月19日

首次发布 (实际的)

2019年7月25日

研究记录更新

最后更新发布 (实际的)

2026年10月22日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • i 82319
  • i 82319 (其他标识符:Roswell Park Cancer Institute)
  • NCI-2019-04326 (注册表标识符:CTRP (Clinical Trial Reporting Program))

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅